

Edgar Filing: Chemtura CORP - Form 10-Q

Chemtura CORP
Form 10-Q
July 29, 2015

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended June 30, 2015

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from _____ to _____
(Commission File Number) 1-15339

CHEMTURA CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

52-2183153

(State or other jurisdiction of incorporation or
organization)

(I.R.S. Employer Identification Number)

1818 Market Street, Suite 3700, Philadelphia, Pennsylvania

19103

199 Benson Road, Middlebury, Connecticut

06749

(Address of principal executive offices)

(Zip Code)

(203) 573-2000

(Registrant's telephone number,
including area code)

(Former name, former address and former fiscal year, if changed from last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T

(§232.405 of the chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "large accelerated filer," "accelerated filer," "non-accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of shares of common stock outstanding as of the latest practicable date is as follows

Class	Number of shares outstanding at June 30, 2015

Common Stock - \$.01 par value

67,811,647

CHEMTURA CORPORATION AND SUBSIDIARIES
FORM 10-Q
FOR THE QUARTER AND SIX MONTHS ENDED JUNE 30, 2015

INDEX	PAGE
<u>PART I. FINANCIAL INFORMATION</u>	<u>2</u>
<u>ITEM 1. Financial Statements</u>	<u>2</u>
<u>Consolidated Statements of Operations (Unaudited)</u>	<u>2</u>
Consolidated Statements of Comprehensive Income (Unaudited)	3
Consolidated Balance Sheets (Unaudited)	4
<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u>	<u>5</u>
<u>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</u>	<u>6</u>
<u>ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>24</u>
<u>ITEM 3. Quantitative and Qualitative Disclosures About Market Risk</u>	<u>37</u>
<u>ITEM 4. Controls and Procedures</u>	<u>38</u>
<u>PART II. OTHER INFORMATION</u>	<u>39</u>
<u>ITEM 1. Legal Proceedings</u>	<u>39</u>
<u>ITEM 1A. Risk Factors</u>	<u>39</u>
<u>ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>39</u>
<u>ITEM 4. Mine Safety Disclosure</u>	<u>40</u>
<u>ITEM 5. Other Information</u>	<u>40</u>
<u>ITEM 6. Exhibits</u>	<u>40</u>
<u>SIGNATURE</u>	<u>41</u>

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

CHEMTURA CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations (Unaudited)

Quarters and six months ended June 30, 2015 and 2014

(In millions, except per share data)

	Quarters ended June 30,		Six months ended June 30,	
	2015	2014	2015	2014
Net sales	\$464	\$609	\$902	\$1,165
Cost of goods sold	350	451	690	887
Selling, general and administrative	41	67	77	127
Depreciation and amortization	24	25	48	53
Research and development	6	10	11	18
Facility closures, severance and related costs	—	4	1	6
Loss on sale of business	—	—	3	—
Equity income	(1) —	(1) —
Operating income	44	52	73	74
Interest expense	(8) (11) (16) (23
Other (expense) income, net	(2) (3) 9	—
Earnings from continuing operations before income taxes	34	38	66	51
Income tax (expense) benefit	(16) 5	(27) 2
Earnings from continuing operations	18	43	39	53
Earnings from discontinued operations, net of tax	—	—	—	1
Gain (loss) on sale of discontinued operations, net of tax	1	(4) —	(9
Net earnings	\$19	\$39	\$39	\$45
Basic per share information				
Earnings from continuing operations	\$0.27	\$0.46	\$0.57	\$0.56
Earnings from discontinued operations, net of tax	—	—	—	0.01
Gain (loss) on sale of discontinued operations, net of tax	0.01	(0.04) —	(0.09
Net earnings	\$0.28	\$0.42	\$0.57	\$0.48
Diluted per share information				
Earnings from continuing operations	\$0.26	\$0.46	\$0.56	\$0.55
Earnings from discontinued operations, net of tax	—	—	—	0.01
Gain (loss) on sale of discontinued operations, net of tax	0.01	(0.04) —	(0.09
Net earnings	\$0.27	\$0.42	\$0.56	\$0.47
Weighted average shares outstanding - Basic	67.6	93.2	68.2	94.8
Weighted average shares outstanding - Diluted	68.5	94.4	69.1	96.1

See accompanying notes to Consolidated Financial Statements.

CHEMTURA CORPORATION AND SUBSIDIARIES
 Consolidated Statements of Comprehensive Income (Unaudited)
 Quarters and six months ended June 30, 2015 and 2014
 (In millions)

	Quarters ended June 30,		Six months ended June 30,	
	2015	2014	2015	2014
Net earnings	\$19	\$39	\$39	\$45
Other comprehensive income (loss), net of tax				
Foreign currency translation adjustments	20	12	(18) 6
Unrecognized pension and other post-retirement benefit costs	3	3	3	4
Unrealized gain on available for sale securities	1	—	5	—
Comprehensive income	\$43	\$54	\$29	\$55

See accompanying notes to Consolidated Financial Statements

CHEMTURA CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

June 30, 2015 (Unaudited) and December 31, 2014

(In millions, except par value data)

	June 30, 2015 (unaudited)	December 31, 2014
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$309	\$392
Accounts receivable, net	264	251
Inventories, net	311	329
Other current assets	158	238
Assets held for sale	—	6
Total current assets	1,042	1,216
NON-CURRENT ASSETS		
Property, plant and equipment, net	677	704
Goodwill	170	172
Intangible assets, net	93	99
Deferred tax asset - non-current	304	313
Other assets	163	163
Total assets	\$2,449	\$2,667
LIABILITIES AND EQUITY		
CURRENT LIABILITIES		
Short-term borrowings	\$3	\$18
Accounts payable	147	146
Accrued expenses	162	170
Below market contract obligation - current	38	38
Income taxes payable	21	24
Liabilities held for sale	—	9
Total current liabilities	371	405
NON-CURRENT LIABILITIES		
Long-term debt	514	556
Pension and post-retirement health care liabilities	297	318
Below market contract obligation - non-current	165	185
Deferred tax liability - non-current	17	25
Other liabilities	110	124
Total liabilities	1,474	1,613
EQUITY		
Common stock - \$0.01 par value Authorized - 500.0 shares Issued - 100.6 shares at June 30, 2015 and 100.5 shares at December 31, 2014	1	1
Additional paid-in capital	4,368	4,383
Accumulated deficit	(2,223) (2,262
Accumulated other comprehensive loss	(407) (397
Treasury stock - at cost - 32.8 shares at June 30, 2015 and 28.8 shares at December 31, 2014	(765) (672
Total Chemtura stockholders' equity	974	1,053
Non-controlling interest	1	1
Total equity	975	1,054
Total liabilities and equity	\$2,449	\$2,667

See accompanying notes to Consolidated Financial Statements.

4

CHEMTURA CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
Six months ended June 30, 2015 and 2014
(In millions)

	Six months ended June 30,	
	2015	2014
Increase (decrease) in cash		
CASH FLOWS FROM OPERATING ACTIVITIES		
Net earnings	\$39	\$45
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:		
Loss on sale of discontinued operations	—	9
Loss on sale of business	3	—
Below market contract obligation	(19) —
Depreciation and amortization	48	53
Share-based compensation expense	6	7
Changes in assets and liabilities, net of assets acquired and liabilities assumed:		
Accounts receivable	(25) (105
Inventories	8	(6
Accounts payable	4	17
Pension and post-retirement health care liabilities	(7) (25
Other	12	(27
Net cash provided by (used in) operating activities	69	(32
CASH FLOWS FROM INVESTING ACTIVITIES		
Net proceeds from divestments	3	16
Sale of Platform Specialty Products Corporation shares	54	—
Capital expenditures	(32) (48
Net cash provided by (used in) investing activities	25	(32
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of long term debt	—	14
Payments on long term debt	(59) (112
Payments on other short-term borrowings, net	—	(1
Common shares acquired	(122) (157
Proceeds from exercise of stock options	13	6
Net cash used in financing activities	(168) (250
CASH AND CASH EQUIVALENTS		
Effect of exchange rates on cash and cash equivalents	(9) —
Change in cash and cash equivalents	(83) (314
Cash and cash equivalents at beginning of period	392	549
Cash and cash equivalents at end of period	\$309	\$235

See accompanying notes to Consolidated Financial Statements.

CHEMTURA CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1) NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

Chemtura Corporation, together with our consolidated subsidiaries, is a global specialty chemical company dedicated to delivering innovative, performance-driven engineered specialty chemical solutions which are used as additives, ingredients or intermediates that add value to our customers' end products. We are committed to global sustainability through "greener technology" and developing engineered chemical solutions that meet our customers' evolving needs. We operate in a wide variety of end-use industries, including automotive, building and construction, electronics, energy, lubricants, packaging and transportation. We are a leader in many of our key product lines and transact business in more than 80 countries.

Our principal executive offices are located in Philadelphia, PA and Middlebury, CT.

When we use the terms "Corporation," "Company," "Chemtura," "Registrant," "We," "Us" and "Our," unless otherwise indicated in the context otherwise requires, we are referring to Chemtura Corporation and our consolidated subsidiaries.

The information in the foregoing Consolidated Financial Statements for the quarters and six months ended June 30, 2015 and 2014 is unaudited but reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the results of operations for the interim periods presented. All such adjustments are of a normal recurring nature, except as otherwise disclosed in the accompanying notes to our Consolidated Financial Statements.

Basis of Presentation

The accompanying Consolidated Financial Statements include the accounts of Chemtura and our wholly-owned and majority-owned subsidiaries that we control. Other affiliates in which we have a 20% to 50% ownership interest or a non-controlling majority interest are accounted for in accordance with the equity method. Other investments in which we have less than 20% ownership are recorded at cost. All significant intercompany balances and transactions have been eliminated in consolidation.

Our Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP"), which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

The interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2014 (the "2014 Form 10-K"). The consolidated results of operations for the quarter ended June 30, 2015 are not necessarily indicative of the results expected for the full year.

Accounting Policies and Other Items

Included in accounts receivable are allowances for doubtful accounts of \$2 million as of June 30, 2015 and December 31, 2014.

During the six months ended June 30, 2015 and 2014, we made cash interest payments of approximately \$16 million and \$22 million, respectively. During the six months ended June 30, 2015 and 2014, we made cash payments for income taxes (net of refunds) of \$20 million and \$10 million, respectively.

At June 30, 2015, \$4 million of our asset retirement obligation was included in accrued expenses and \$13 million was included in other liabilities in our Consolidated Balance Sheet. At December 31, 2014, \$3 million of our asset retirement obligation was included in accrued expenses and \$13 million was included in other liabilities in our Consolidated Balance Sheet.

Accounting Developments

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. This ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective on January 1, 2018. Early application is permitted in 2017 for calendar year entities. We currently do not intend to

early adopt. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that the ASU will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.

In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs. Under current U.S. GAAP, debt issuance costs are reported on the balance sheet as assets and amortized as interest expense. This ASU requires that they be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability, which is similar to the presentation of debt discounts or premiums. The costs will continue to be amortized to interest expense using the effective interest method. This ASU is effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We do not expect the adoption of this ASU to have a material impact on our financial statements.

2) DIVESTITURES

Divestitures Reported as Gain or Loss on Sale of Business

In November 2014, we sold our Chemtura AgroSolutions business to Platform Specialty Products Corporation ("Platform") under a Stock and Asset Purchase Agreement ("SAPA") for approximately \$1 billion, consisting of \$950 million in cash and 2 million shares of Platform's common stock. The purchase price was subject to customary post-closing adjustments, primarily for working capital which was settled in the quarter ended June 30, 2015. During the second quarter of 2015, we sold all 2 million shares of Platform common stock for net proceeds of \$54 million. As a result of holding the shares, which were accounted for as available for sale securities, we reported a net gain of \$3 million in the second quarter of 2015 which is included in other (expense) income, net in the Consolidated Statement of Operations.

Under the terms of the SAPA, we retained most of the property, plant and equipment used to manufacture products of the Chemtura AgroSolutions business and continue to manufacture products for Platform under several supply agreements and a tolling agreement (collectively, the "supply agreements") with minimum terms of between two and four years. In alignment with the change in the nature of operations, we changed the name of this segment to Agrochemical Manufacturing.

The supply agreements with Platform are designed to recover the cash costs incurred to manufacture the products under the agreement. Accordingly, the supply agreements are considered below-market contracts for their full term. As of June 30, 2015, our Consolidated Balance Sheet included \$203 million, which represents the remaining loss of profit, on a discounted basis, for these products over the remaining terms of the supply agreements, including contractual obligations to continue to supply for a period of up to 2 years after the termination of the supply agreements.

The recognition of this obligation, along with the accretion of the obligation to its undiscounted value, has been and will continue to be recorded as net sales in the Agrochemical Manufacturing segment on a straight-line basis over the term of each supply agreement based on our estimate of the timing of shipments. The recognition of this obligation will not generate cash flows during the term of the supply agreements. As of June 30, 2015, the current and long-term portions of this obligation, on a discounted basis, were \$38 million and \$165 million, respectively.

As of December 31, 2014, we had not transferred ownership of our wholly-owned subsidiary in Russia and our 15% investment in Certis Europe B.V. ("Certis") to Platform as provided in the SAPA due to certain pending approvals. Therefore, the value of these assets and liabilities along with the proceeds received for these investments were presented as assets and liabilities held for sale as of that date. The value ascribed to these investments as part of the purchase price was received at the closing in November 2014.

We closed on the sale of our subsidiary in Russia in January 2015 and we transferred our shares in Certis to Platform during the second quarter of 2015.

The following is a summary of the Chemtura AgroSolutions assets and liabilities held for sale as of December 31, 2014:

(In millions)	December 31, 2014
Accounts receivable, net	3
Inventories	1
Other assets	2
Assets	6
Accrued expenses	9
Liabilities	9
Net Assets	(3)

Included in the loss on sale of business for the six months ended June 30, 2015 is the working capital adjustment that was settled in the second quarter of 2015 and the sale of our wholly-owned subsidiary in Russia in the first quarter of 2015.

Divestitures Reported as Discontinued Operations

In December 2013, we sold our Consumer Products business to KIK Custom Products Inc. ("KIK") and in April 2013, we sold substantially all the assets of our Antioxidant business (the "Antioxidant Sale") to SK Blue Holdings, Ltd. ("SK"), an affiliate of SK Capital Partners III, L.P., and Addivant USA Holdings Corp ("Addivant"). During the six months ended June 30, 2014, we recognized a pre-tax loss of \$9 million (\$9 million after tax) primarily for post-closing adjustments and obligations, settlement of working capital claims and fees associated with those adjustments and claims which were recognized in loss on sale of discontinued operations, net of tax in the Consolidated Statement of Operations.

3) RESTRUCTURING ACTIVITIES

We recorded pre-tax charges of \$1 million and \$6 million during the six months ended June 30, 2015 and 2014, respectively, to facility closures, severance and related costs in our Consolidated Statements of Operations. The 2015 charge was mainly for severance related to the planned closure of our West Lafayette, IN facility that was initiated in February 2015 under the restructuring plan approved by our Board of Directors (the "Board") in November 2014. The 2014 charge was primarily for severance and professional fees related to our organizational restructuring plan that was approved by the Board in 2013.

A summary of the changes in the liabilities established for restructuring programs during the six months ended June 30, 2015 is as follows:

(In millions)	Severance and Related Costs
Balance at December 31, 2014	\$21
2015 charge	1
Cash payments	(15)
Balance at June 30, 2015	\$7

At June 30, 2015 and December 31, 2014, the balance of these reserves were included in accrued expenses in our Consolidated Balance Sheet.

4) INVENTORIES

(In millions)	June 30, 2015	December 31, 2014
Finished goods	\$192	\$200
Work in process	37	35
Raw materials and supplies	82	94
	\$311	\$329

Included in the above net inventory balances are inventory obsolescence reserves of approximately \$13 million at June 30, 2015 and December 31, 2014.

5) PROPERTY, PLANT AND EQUIPMENT

(In millions)	June 30, 2015	December 31, 2014
Land and improvements	\$70	\$71
Buildings and improvements	200	209
Machinery and equipment	1,200	1,248
Information systems equipment	165	167
Furniture, fixtures and other	20	22
Construction in progress	82	82
	1,737	1,799
Less: accumulated depreciation	1,060	1,095
	\$677	\$704

Depreciation expense was \$21 million for the quarters ended June 30, 2015 and 2014, and \$42 million and \$44 million for the six months ended June 30, 2015 and 2014, respectively. Depreciation expense included accelerated depreciation of certain fixed assets associated with our restructuring programs of \$1 million for the quarters ended June 30, 2015 and 2014, and \$2 million and \$4 million for the six months ended June 30, 2015 and 2014, respectively.

6) GOODWILL AND INTANGIBLE ASSETS

Goodwill was \$170 million and \$172 million at June 30, 2015 and December 31, 2014, respectively. The decrease in goodwill since December 31, 2014 was due to foreign currency translation. The goodwill is allocated to the Industrial Performance Products segment.

Our intangible assets (excluding goodwill) consist of Patents, Trademarks, Customer Relationships, Production Rights and Other Intangibles. At June 30, 2015 and December 31, 2014, our net intangible assets were \$93 million and \$99 million, respectively. The decrease was due to amortization expense. Amortization expense related to intangible assets was \$3 million and \$4 million for the quarters ended June 30, 2015 and 2014, respectively, and \$6 million and \$9 million for the six months ended June 30, 2015 and 2014, respectively.

7) DEBT

Our debt is comprised of the following:

(In millions)	June 30, 2015		December 31, 2014	
	Carrying Value	Fair Value	Carrying Value	Fair Value
5.75% Senior Notes due 2021	\$450	\$457	\$450	\$439
Term Loan due 2016	40	40	82	82
Other borrowings	27	27	42	42
Total Debt	517	524	574	563
Less: Other short-term borrowings	(3))	(18))
Total Long-term debt	\$514		\$556	

Financing Facilities

2021 Senior Notes

In July 2013, we completed a registered public offering of \$450 million of 5.75% Senior Notes due 2021 (the "2021 Senior Notes").

At any time prior to July 15, 2016, we are permitted to redeem some or all of the 2021 Senior Notes at a redemption price equal to 100% of the principal amount thereof plus a make-whole premium (as defined in the indenture governing the 2021 Senior Notes (the "2021 Indenture")) and accrued and unpaid interest up to, but excluding, the redemption date. At any time after July 15, 2016, we are permitted to redeem some or all of the 2021 Senior Notes, with the redemption prices being, prior to July 15,

2017, 104.313% of the principal amount; on or after July 15, 2017 and prior to July 15, 2018, 102.875% of the principal amount; on or after July 15, 2018 and prior to July 15, 2019, 101.438% of the principal amount; and thereafter 100% of the principal amount, in each case plus any accrued and unpaid interest to the redemption date. In addition, prior to July 15, 2016, we may redeem up to 35% of the 2021 Senior Notes from the proceeds of certain equity offerings at a redemption price of 105.75% plus accrued but unpaid interest to the redemption date. If we experience certain kinds of changes in control, as defined in the 2021 Indenture, we may be required to offer to repurchase all of the 2021 Senior Notes at a redemption price (subject to limitations as described in the 2021 Indenture) equal to 101% of the aggregate principal amount plus accrued and unpaid interest.

Our 2021 Senior Notes contain covenants that limit our ability to enter into certain transactions, such as incurring secured debt and subsidiary debt and entering into sale and lease-back transactions.

Our 2021 Senior Notes are subject to certain events of default, including, among others, breach of other agreements in the 2021 Indenture; any guarantee of a significant subsidiary ceasing to be in full force and effect; a default by us or our restricted subsidiaries under any bonds, debentures, notes or other evidences of indebtedness of a certain amount, resulting in its acceleration; and certain events of bankruptcy or insolvency.

Term Loan

In August 2010, we entered into the Term Loan due 2016 with Bank of America, N.A., as administrative agent, and other lenders party thereto for an aggregate principal amount of \$295 million with an original issue discount of 1%. The Term Loan permitted us to increase the size of the facility with an accordion feature by up to \$125 million. Repayments were made on the Term Loan in 2013 and 2014 with proceeds from the 2021 Senior Notes offering, the cash proceeds from the sale of businesses and cash on hand. In May 2015, we made an additional repayment of \$42 million. As of June 30, 2015, \$40 million remained outstanding under the Term Loan.

Borrowings under the amended Term Loan bear interest at a rate per annum equal to, at our election, (i) 1.75% plus the Base Rate (defined as the higher of (a) the Federal Funds rate plus 0.5%; (b) Bank of America's published prime rate; and (c) the Eurodollar Rate plus 1%) or (ii) 2.75% plus the Eurodollar Rate (defined as the higher of (a) 0.75% and (b) the current LIBOR adjusted for reserve requirements).

The Term Loan contains covenants that limit, among other things, our ability to enter into certain transactions, such as creating liens, incurring additional indebtedness or repaying certain indebtedness, making investments, paying dividends, and entering into acquisitions, dispositions and joint ventures.

Additionally, the Term Loan requires that we meet certain financial maintenance covenants including a maximum Secured Leverage Ratio (net of unrestricted cash, as defined in the agreement) of 2.5:1.0 and a minimum Consolidated Interest Coverage Ratio (as defined in the agreement) of 3.0:1.0. Additionally, the Term Loan contains a covenant related to the repayment of excess cash flow (as defined in the agreement). As of June 30, 2015, we were in compliance with the covenant requirements of the Term Loan.

ABL Facility

In December 2013, we entered into a five-year senior secured revolving credit facility that provides for \$175 million available to our domestic subsidiaries (the "US ABL Facility") and €60 million available to Chemtura Sales Europe B.V., a Netherlands subsidiary (the "Foreign ABL Facility", and together with the US ABL Facility, the "2018 ABL Facility"), subject in each case to availability under a borrowing base. The 2018 ABL Facility provides a \$125 million letter of credit sub-facility.

The revolving loans under the 2018 ABL Facility will bear interest at a rate per annum which, at our option, can be either: (a) a base rate (which varies depending on the currency in which the loans are borrowed) plus a margin of between 0.50% and 1.00% for loans denominated in U.S. dollars or between 1.50% and 2.00% for loans denominated in other currencies, in each case based on the average excess availability under the 2018 ABL Facility for the preceding quarter; or (b) the current reserve adjusted Eurocurrency Rate plus a margin of between 1.50% and 2.00% based on the average excess availability under the 2018 ABL Facility for the preceding quarter.

The 2018 ABL Facility Agreement contains certain affirmative and negative covenants (applicable to us, the other borrowing subsidiaries, the guarantors and their respective subsidiaries other than unrestricted subsidiaries), including, without limitation, covenants requiring financial reporting and notices of certain events, and covenants imposing limitations on incurrence of indebtedness and guaranties; liens; loans and investments; asset dispositions; dividends, redemptions, and repurchases of stock

and prepayments, redemptions and repurchases of certain indebtedness; mergers, consolidations, acquisitions, joint ventures or creation of subsidiaries; material changes in business; transactions with affiliates; restrictions on distributions from restricted subsidiaries and granting of negative pledges; changes in accounting and reporting; sale leasebacks; and speculative transactions, and a springing financial covenant requiring a minimum trailing four quarter fixed charge coverage ratio of 1.0 to 1.0 at all times during (A) any period from the date when the amount available for borrowings under the 2018 ABL Facility falls below the greater of (i) \$25 million and (ii) 10% of the aggregate commitments to the date such available amount has been equal to or greater than the greater of (i) \$25 million and (ii) 10% of the aggregate commitments for 30 consecutive days, or (B) any period from the date when the amount available for borrowings under the US ABL Facility falls below the greater of (i) \$18 million and (ii) 10% of the aggregate commitments under the US ABL Facility to the date such available amount has been equal to or greater than the greater of (i) \$18 million and (ii) 10% of the aggregate commitments under the US ABL Facility for 30 consecutive days.

At June 30, 2015 and December 31, 2014, we had no borrowings under the 2018 ABL Facility. However, we had \$14 million and \$15 million of outstanding letters of credit (primarily related to insurance obligations, environmental obligations and banking credit facilities) which utilizes available capacity under the facility. At June 30, 2015 and December 31, 2014, we had approximately \$200 million and \$211 million, respectively, of undrawn availability under the 2018 ABL Facility.

Other Facilities

In December 2012, we entered into a CNY 250 million (approximately \$40 million) 5 year secured credit facility available through December 2017 (the "China Bank Facility") with Agricultural Bank of China, Nantong Branch (the "ABC Bank"). The China Bank Facility has been used for funding construction of our manufacturing facility in Nantong, China and is secured by land, property and machinery of our subsidiary Chemtura Advanced Materials (Nantong) Co., Ltd. The loans under the China Bank Facility bear interest at a rate determined from time to time by ABC Bank based on the prevailing People's Bank of China Lending Rate. Repayments of principal will be made in semi-annual installments from December 2014 through December 2017. In January 2015, we prepaid \$15 million of the China Bank Facility with proceeds from the sale of the Chemtura AgroSolutions business. At June 30, 2015 and December 31, 2014, we had borrowings of \$12 million and \$27 million, respectively, under the China Bank Facility.

8) INCOME TAXES

We reported income tax expense of \$16 million and a benefit of \$5 million for the quarters ended June 30, 2015 and 2014, respectively, and income tax expense of \$27 million and a benefit of \$2 million for the six months ended June 30, 2015 and 2014, respectively. The tax expense reported for the quarter and six months ended June 30, 2015 reflected higher earnings. In addition, following the release of U.S. valuation allowance in the fourth quarter of 2014, we recorded a full tax provision on our U.S. income. In the fourth quarter of 2014, we concluded that the positive evidence outweighed the negative evidence concerning our ability to use our U.S. deferred tax assets before they expire. As a result, we released a majority of our U.S. valuation allowance in the fourth quarter of 2014.

The tax benefit reported for quarter and six months ended June 30, 2014 included a decrease in foreign income taxes of approximately \$15 million related to an unrecognized tax benefit that had been recorded for an international jurisdiction in prior years. The tax benefit was recorded after reaching an agreement with the international jurisdiction that effectively settles the prior year liability.

We have net liabilities related to unrecognized tax benefits of \$28 million at June 30, 2015 and December 31, 2014.

9) ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of accumulated other comprehensive loss (“AOCL”), net of tax at June 30, 2015 and December 31, 2014, were as follows:

(in millions)	Foreign Currency Translation Adjustments	Unrecognized Pension and Other Post-Retirement Benefit Costs	Unrealized loss on available for sale securities	Total
As of December 31, 2014	\$ (86)	\$ (306)	\$ (5)	\$ (397)
Other comprehensive income (loss) before reclassifications	(23)	(5)	6	(22)
Amounts reclassified from AOCL	5	8	(1)	12
Net current period other comprehensive (loss) income	(18)	3	5	(10)
As of June 30, 2015	\$ (104)	\$ (303)	\$—	\$ (407)

The following table summarizes the reclassifications from AOCL to the Consolidated Statement of Operations for the quarters and six months ended June 30, 2015 and 2014:

(in millions)	Amount Reclassified from AOCL				Affected line item in the consolidated statement of operations
	Quarters ended June 30,		Six months ended June 30,		
	2015	2014	2015	2014	
Foreign currency translation items:					
Loss on sale of business (a)	\$—	\$—	\$ (5)	\$—	Loss on sale of business
Net of tax	—	—	(5)	—	
Defined benefit pension plan items:					
Amortization of prior-service costs (b)	1	1	2	2	Primarily SG&A
Amortization of actuarial losses (b)	(4)	(4)	(11)	(8)	Primarily SG&A
Total before tax	(3)	(3)	(9)	(6)	
Total tax	—	1	1	1	Income Tax Expense
Net of tax	(3)	(2)	(8)	(5)	
Sale of available for sale securities:					
Gain on sale of Platform stock	2	—	2	—	Other (expense) income, net
Total tax	(1)	—	(1)	—	Income Tax Expense
Net of tax	1	—	1	—	
Total reclassifications	\$ (2)	\$ (2)	\$ (12)	\$ (5)	

(a) Sale of the Chemtura AgroSolutions business (see Note 2 - Divestitures).

(b) These items are included in the computation of net periodic benefit pension cost (see Note 12 - Pension and other Post-Retirement Benefit Plans for additional information).

10) COMMON SHARES

The computation of basic earnings per common share is based on the weighted average number of common shares outstanding. The computation of diluted earnings per common share is based on the weighted average number of

common and common share equivalents outstanding.

The following is a reconciliation of the shares used in the computation of earnings per share:

12

(In millions)	Quarters ended June 30,		Six months ended June 30,	
	2015	2014	2015	2014
Weighted average shares outstanding - Basic	67.6	93.2	68.2	94.8
Dilutive effect of common share equivalents	0.9	1.2	0.9	1.3
Weighted average shares outstanding - Diluted	68.5	94.4	69.1	96.1

In October 2014, the Board approved a share repurchase authorization of up to \$500 million conditioned upon the sale of the Chemtura AgroSolutions business. This repurchase program will expire on December 1, 2015.

During the six months ended June 30, 2015, we repurchased 5.1 million shares of our common stock at a cost of \$122 million. As of June 30, 2015, \$48 million remained under the share repurchase program.

The shares are expected to be repurchased from time to time through open market purchases. The program does not obligate us to repurchase any particular amount of common stock and may be modified or suspended at any time at the Board's discretion. The manner, price, number and timing of such repurchases, if any, will be subject to a variety of factors, including market conditions and the applicable rules and regulations of the SEC. We release the value of treasury shares at the weighted average price per share when shares are issued from treasury.

11) STOCK INCENTIVE PLANS

In 2010, we adopted the Chemtura Corporation 2010 Long-Term Incentive Plan (the "2010 LTIP"). The 2010 LTIP provides for grants of nonqualified stock options ("NQOs"), incentive stock options ("ISOs"), stock appreciation rights, dividend equivalent rights, stock units, bonus stock, performance awards, share awards, restricted stock, time-based restricted stock units ("RSUs") and performance-based RSUs. The 2010 LTIP provides for the issuance of a maximum of 11 million shares. Stock options may be granted under the 2010 LTIP at prices equal to the fair market value of the underlying common shares on the date of the grant. All outstanding stock options will expire not more than ten years from the date of the grant. Stock issuances can be from treasury shares or newly issued shares.

Share-based compensation expense was \$3 million for the quarters ended June 30, 2015 and 2014, and \$6 million and \$7 million for the six months ended June 30, 2015 and 2014, respectively. Stock-based compensation expense was primarily reported in SG&A.

Restricted Stock Units and Performance Shares

In March 2015, the compensation and governance committee of the Board (the "Compensation Committee") approved the grant of 0.2 million time-based RSUs under the 2015 long-term incentive awards (the "2015 Awards"). These RSUs vest ratably over a three-year period.

In March 2015, the Compensation Committee also approved the grant of 0.2 million performance shares under the 2015 Awards. The share grant is subject to a performance multiplier of up to 2 times the targeted award. The performance measurement period is the three calendar year period ending December 31, 2017 and the performance share metric is the relative total shareholder return against the companies comprising the Dow Jones Chemical Index. The performance shares will be settled as soon as practicable after the performance period but no later than March 15, 2018. We used the Monte-Carlo simulation model to determine the fair value of the performance shares. Using this method, the average per share fair value of these awards was \$34.91.

Total remaining unrecognized compensation expense associated with all unvested time-based RSUs and performance shares at June 30, 2015 was \$17 million, which will be recognized over the weighted average period of approximately 2 years.

12) PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS

Components of our defined benefit plans net periodic benefit (credit) cost for the quarters and six months ended June 30, 2015 and 2014 are as follows:

(In millions)	Defined Benefit Plans						
	Qualified U.S. Plans		International and Non-Qualified Plans		Post-Retirement Health Care Plans		
	Quarters ended June 30,		Quarters ended June 30,		Quarters ended June 30,		
	2015	2014	2015	2014	2015	2014	
Service cost	\$—	\$—	\$1	\$1	\$—	\$—	
Interest cost	6	7	5	5	1	1	
Expected return on plan assets	(10) (10) (6) (7) —	—	
Amortization of prior service cost	—	—	—	—	(1) (1)
Amortization of actuarial losses	3	3	1	1	—	—	
Net periodic benefit cost (credit)	\$(1) \$—	\$1	\$—	\$—	\$—	

(In millions)	Defined Benefit Plans						
	Qualified U.S. Plans		International and Non-Qualified Plans		Post-Retirement Health Care Plans		
	Six months ended June 30,		Six months ended June 30,		Six months ended June 30,		
	2015	2014	2015	2014	2015	2014	
Service cost	\$—	\$—	\$1	\$1	\$—	\$—	
Interest cost	12	14	9	10	2	2	
Expected return on plan assets	(20) (20) (12) (13) —	—	
Amortization of prior service cost	—	—	—	—	(2) (2)
Amortization of actuarial losses	7	5	3	2	1	1	
Net periodic benefit cost (credit)	\$(1) \$(1) \$1	\$—	\$1	\$1	

We contributed \$1 million to our U.S. non-qualified pension plans and \$4 million to our international pension plans for the six months ended June 30, 2015. Contributions to post-retirement health care plans for the six months ended June 30, 2015 were \$4 million.

13) LEGAL PROCEEDINGS AND CONTINGENCIES

We are involved in claims, litigation, administrative proceedings and investigations of various types in a number of jurisdictions. A number of such matters involve, or may involve, claims for a material amount of damages and relate to or allege, among other things, environmental liabilities, including clean-up costs associated with hazardous waste disposal sites, natural resource damages, property damage and personal injury.

Litigation and Claims

Environmental Liabilities

We are involved in environmental matters of various types in a number of jurisdictions. These matters may, from time to time, involve claims for material amounts of damages and relate to or allege environmental liabilities, including clean up costs associated with hazardous waste disposal sites and natural resource damages.

The Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended (“CERCLA”), and comparable state statutes impose strict liability upon various classes of persons with respect to the costs associated with the investigation and remediation of waste disposal sites. Such persons are typically referred to as “Potentially Responsible Parties” or PRPs. Because in certain circumstances these laws have been construed to authorize the imposition of joint and several liability, the Environmental Protection Agency (“EPA”) and comparable state agencies could seek to recover all costs involving a waste disposal site from any one of the PRPs for such site, including Chemtura, despite the involvement of other PRPs. Currently, we are one of a large number of PRPs with respect to a site in which we hold the majority of the liability. Chemtura and its subsidiaries may be named as PRPs at other sites in the future. In addition, we are involved with environmental remediation and compliance activities at some of our current and former sites in the United States and abroad.

Each quarter, we evaluate and review estimates for future remediation and other costs to determine appropriate environmental reserve amounts. For each site where the cost of remediation is probable and reasonably estimable, we determine the specific measures that are believed to be required to remediate the site, the estimated total cost to carry out the remediation plan, the portion of the total remediation costs to be borne by us and the anticipated time frame over which payments toward the

14

remediation plan will occur. At sites where we expect to incur ongoing operation and maintenance expenditures, we accrue on an undiscounted basis for a period of generally 10 years those costs which we believe are probable and estimable.

The total amount accrued for environmental liabilities as of June 30, 2015 and December 31, 2014 was \$69 million and \$76 million, respectively. At June 30, 2015 and December 31, 2014, \$21 million and \$17 million, respectively, of these environmental liabilities were reflected as accrued expenses and \$48 million and \$59 million, respectively, were reflected as other liabilities. We estimate that ongoing environmental liabilities could range up to \$80 million at June 30, 2015. Our accruals for environmental liabilities include estimates for determinable clean-up costs. We recorded pre-tax charges of \$4 million for the six months ended June 30, 2015 and made payments of \$7 million during the six months ended June 30, 2015 for clean-up costs, which reduced our environmental liabilities. At certain sites, we have contractual agreements with certain other parties to share remediation costs. As of June 30, 2015, no receivables are outstanding related to these agreements. At a number of these sites, the extent of contamination has not yet been fully investigated or the final scope of remediation is not yet determinable. We intend to assert all meritorious legal defenses and will pursue other equitable factors that are available with respect to these matters. However, the final cost of clean-up at these sites could exceed our present estimates, and could have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations, or cash flows. Our estimates for environmental remediation liabilities may change in the future should additional sites be identified, further remediation measures be required or undertaken, current laws and regulations be modified or additional environmental laws and regulations be enacted, and as negotiations with respect to certain sites.

Other

We are routinely subject to civil claims, litigations, arbitrations, and regulatory investigations arising in the ordinary course of our business, as well as in respect of our divested businesses. Some of these claims and litigations relate to product liability claims, including claims related to our current and historical products and asbestos-related claims concerning premises and historic products of our corporate affiliates and predecessors.

Guarantees

In addition to the letters of credit of \$14 million and \$15 million outstanding at June 30, 2015 and December 31, 2014, respectively, we have guarantees that have been provided to various financial institutions. At June 30, 2015 and December 31, 2014, we had \$8 million and \$10 million of outstanding guarantees, respectively. The letters of credit and guarantees were primarily related to liabilities for insurance obligations, environmental obligations, banking and credit facilities, vendor deposits and European value added tax ("VAT") obligations.

In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on our behalf or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation, claims or environmental matters relating to our past performance. For any losses that we believe are probable and estimable, we have accrued for such amounts in our Consolidated Balance Sheets.

14) BUSINESS SEGMENT DATA

We evaluate a segment's performance based on several factors, of which the primary factor is operating income (loss). In computing operating income (loss) by segment, the following items have not been deducted: (1) general corporate expense; (2) amortization; (3) facility closures, severance and related costs and (4) gain or loss on sale of business. Pursuant to ASC Topic 280, Segment Reporting ("ASC 280"), these items have been excluded from our presentation of segment operating income (loss) because they are not reported to the chief operating decision maker for purposes of allocating resources among reporting segments or assessing segment performance.

Industrial Performance Products

Industrial Performance Products are engineered solutions for our customers' specialty chemical needs. Industrial Performance Products include petroleum additives that provide detergency, friction modification and corrosion protection in automotive lubricants, greases, refrigeration and turbine lubricants as well as synthetic lubricant base-stocks and greases; castable urethane prepolymers engineered to provide superior abrasion resistance and durability in many industrial and recreational applications; and polyurethane dispersions and urethane prepolymers used in various types of coatings such as clear floor finishes, high-gloss paints and textiles treatments. These products

are sold directly to manufacturers and through distribution channels.

15

Industrial Engineered Products

Industrial Engineered Products are chemical additives designed to improve the performance of polymers in their end-use applications. Industrial Engineered Products include brominated performance products, flame retardants, fumigants and organometallics. The products are sold across the entire value chain ranging from direct sales to monomer producers, polymer manufacturers, compounders and fabricators, manufactures of electronic components, fine chemical manufacturers, utilities, pharmaceutical manufactures and oilfield service companies to industry distributors.

Agrochemical Manufacturing (formerly Chemtura AgroSolutions)

In November 2014, we sold our Chemtura AgroSolutions business to Platform. Under the terms of the SAPA, we retained most of the property, plant and equipment used to manufacture products of the Chemtura AgroSolutions business and continue to manufacture products for Platform under several supply agreements with minimum terms of between two and four years. In alignment with the change in the nature of operations, we changed the name of this segment to Agrochemical Manufacturing.

The supply agreements with Platform are designed to recover the cash costs incurred to manufacture the products under the agreement. Due to these economics, the supply agreements are considered below-market contracts for their full term. At closing, an obligation was recorded, on a discounted basis, which represents the remaining loss of profit on these products over the remaining terms of the supply agreements, including contractual obligations to continue to supply for a period of up to 2 years after the termination of the contracts. The recognition of this obligation, along with the accretion of the obligation to its undiscounted value, has been and will continue to be recorded as net sales in the Agrochemical Manufacturing segment on a straight-line basis over the term of each supply agreement based on our estimate of the timing of shipments. The recognition of this obligation will not generate cash flows during the term of the supply agreements.

Corporate and Other Charges

Corporate includes costs and expenses that are of a general corporate nature or managed on a corporate basis. These costs (net of allocations to the business segments) primarily represent corporate stewardship and administration activities together with costs associated with legacy activities and intangible asset amortization. Functional costs are allocated between the business segments and general corporate expense. Facility closures, severance and related costs are primarily for severance costs related to our cost savings initiatives. The loss on sale of business relates to the sale of our Chemtura AgroSolutions business in 2014.

A summary of business data for our reportable segments for the quarters and six months ended June 30, 2015 and 2014 are as follows:

(In millions)	Quarters ended June 30,		Six months ended June 30,	
	2015	2014	2015	2014
Net Sales				
Petroleum additives	\$ 158	\$ 183	\$ 317	\$ 354
Urethanes	72	76	145	152
Industrial Performance Products	230	259	462	506
Bromine based & related products	158	168	297	334
Organometallics	39	42	75	84
Industrial Engineered Products	197	210	372	418
Agrochemical Manufacturing	37	140	68	241
Total net sales	\$ 464	\$ 609	\$ 902	\$ 1,165

Edgar Filing: Chemtura CORP - Form 10-Q

(In millions)	Quarters ended June 30,		Six months ended June 30,	
	2015	2014	2015	2014
Operating Income				
Industrial Performance Products	\$38	\$26	\$74	\$53
Industrial Engineered Products	15	16	17	12
Agrochemical Manufacturing	10	36	18	58
	63	78	109	123
General corporate expense, including amortization	(19) (22) (32) (43
Facility closures, severance and related costs	—	(4) (1) (6
Loss on sale of business	—	—	(3) —
Total operating income	\$44	\$52	\$73	\$74

17

15) GUARANTOR CONDENSED CONSOLIDATING FINANCIAL DATA

Our obligations under the 2021 Senior Notes are fully and unconditionally guaranteed on a senior unsecured basis, jointly and severally, by each current and future domestic restricted subsidiary, other than excluded subsidiaries that guarantee any indebtedness of Chemtura or our restricted subsidiaries. Our subsidiaries that do not guarantee the 2021 Senior Notes are referred to as the “Non-Guarantor Subsidiaries.” The Guarantor Condensed Consolidating Financial Data presented below presents the statements of operations, statements of comprehensive income (loss), balance sheets and statements of cash flow for: (i) Chemtura Corporation (the “Parent Company”), the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries on a consolidated basis (which is derived from Chemtura historical reported financial information); (ii) the Parent Company, alone (accounting for our Guarantor Subsidiaries and the Non-Guarantor Subsidiaries on an equity basis under which the investments are recorded by each entity owning a portion of another entity at cost, adjusted for the applicable share of the subsidiary’s cumulative results of operations, capital contributions and distributions, and other equity changes); (iii) the Guarantor Subsidiaries alone; and (iv) the Non-Guarantor Subsidiaries alone.

Condensed Consolidating Statement of Operations

Quarter ended June 30, 2015

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net sales	\$464	\$(356)) \$304	\$110	\$406
Cost of goods sold	350	(356)) 260	80	366
Selling, general and administrative	41	—	25	4	12
Depreciation and amortization	24	—	6	10	8
Research and development	6	—	4	1	1
Facility closures, severance and related costs	—	—	—	1	(1)
Loss (gain) on sale of business	—	—	14	—	(14)
Equity income	(1)) —	(1)) —	—
Operating income (loss)	44	—	(4)) 14	34
Interest expense	(8)) —	(8)) —	—
Other (expense) income, net	(2)) —	4	—	(6)
Equity in net earnings of subsidiaries	—	(30)) 30	—	—
Earnings from continuing operations before income taxes	34	(30)) 22	14	28
Income tax expense	(16)) —	(4)) —	(12)
Earnings from continuing operations	18	(30)) 18	14	16
Gain on sale of discontinued operations, net of tax	1	—	1	—	—
Net earnings	\$19	\$(30)) \$19	\$14	\$16

Condensed Consolidating Statement of Operations
Six months ended June 30, 2015
(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net sales	\$902	\$(699)	\$593	\$207	\$801
Cost of goods sold	690	(699)	505	160	724
Selling, general and administrative	77	—	49	6	22
Depreciation and amortization	48	—	11	20	17
Research and development	11	—	6	2	3
Facility closures, severance and related costs	1	—	—	2	(1)
Loss (gain) on sale of business	3	—	12	—	(9)
Equity income	(1)	—	(1)	—	—
Operating income	73	—	11	17	45
Interest expense	(16)	—	(17)	—	1
Other income (expense), net	9	—	9	2	(2)
Equity in net earnings of subsidiaries	—	(45)	45	—	—
Earnings from continuing operations before income taxes	66	(45)	48	19	44
Income tax expense	(27)	—	(9)	—	(18)
Net earnings	\$39	\$(45)	\$39	\$19	\$26

Condensed Consolidating Statement of Comprehensive Income
Quarter ended June 30, 2015
(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net earnings	\$19	\$(30)	\$19	\$14	\$16
Other comprehensive income (loss), net of tax					
Foreign currency translation adjustments	20	—	(5)	—	25
Unrecognized pension and other post-retirement benefit costs	3	—	3	—	—
Unrealized gain on available for sale securities	1	—	1	—	—
Comprehensive income	\$43	\$(30)	\$18	\$14	\$41

Condensed Consolidating Statement of Comprehensive Income
Six months ended June 30, 2015
(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net earnings	\$39	\$(45)	\$39	\$19	\$26
Other comprehensive (loss) income, net of tax					
Foreign currency translation adjustments	(18)	—	11	—	(29)
Unrecognized pension and other post-retirement benefit costs	3	—	1	—	2
Unrealized gain on available for sale securities	5	—	5	—	—

Edgar Filing: Chemtura CORP - Form 10-Q

Comprehensive income	\$29	\$(45) \$56	\$19	\$(1)
----------------------	------	-------	--------	------	------	---

19

Condensed Consolidating Balance Sheet

As of June 30, 2015

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
ASSETS					
Current assets	\$1,042	\$—	\$469	\$103	\$470
Intercompany receivables	—	(1,770)	568	281	921
Investment in subsidiaries	—	(4,895)	799	1,135	2,961
Property, plant and equipment	677	—	112	217	348
Goodwill	170	—	93	3	74
Other assets	560	—	439	33	88
Total assets	\$2,449	\$(6,665)	\$2,480	\$1,772	\$4,862
LIABILITIES AND EQUITY					
Current liabilities	\$371	\$—	\$155	\$44	\$172
Intercompany payables	—	(1,770)	491	526	753
Long-term debt	514	—	500	—	14
Other long-term liabilities	589	—	359	80	150
Total liabilities	1,474	(1,770)	1,505	650	1,089
Total equity	975	(4,895)	975	1,122	3,773
Total liabilities and equity	\$2,449	\$(6,665)	\$2,480	\$1,772	\$4,862

Condensed Consolidating Statement of Cash Flows

Six months ended June 30, 2015

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Increase (decrease) to cash					
CASH FLOWS FROM OPERATING ACTIVITIES					
Net earnings	\$ 39	\$ (45)	\$ 39	\$ 19	\$ 26
Adjustments to reconcile net earnings to net cash provided by operations:					
Loss on sale of business	3	—	12	—	(9)
Below market contract obligation	(19)	—	(18)	—	(1)
Depreciation and amortization	48	—	11	20	17
Share-based compensation expense	6	—	6	—	—
Changes in assets and liabilities, net	(8)	45	(6)	(26)	(21)
Net cash provided by operations	69	—	44	13	12
CASH FLOWS FROM INVESTING ACTIVITIES					
Net proceeds from divestments	3	—	4	—	(1)
Sale of Platform Specialty Products Corporation shares	54	—	54	—	—
Capital expenditures	(32)	—	(4)	(13)	(15)
Net cash provided by (used in) investing activities	25	—	54	(13)	(16)

**CASH FLOWS FROM FINANCING
ACTIVITIES**

Payments on long term debt	(59) —	(43) —	(16)
Common shares acquired	(122) —	(122) —	—)
Proceeds from the exercise of stock options	13	—	13	—	—)
Net cash used in financing activities	(168) —	(152) —	(16)
CASH AND CASH EQUIVALENTS						
Effect of exchange rates on cash and cash equivalents	(9) —	—	—	(9)
Change in cash and cash equivalents	(83) —	(54) —	(29)
Cash and cash equivalents at beginning of period	392	—	227	—	165)
Cash and cash equivalents at end of period	\$ 309	\$ —	\$ 173	\$ —	\$ 136)

Edgar Filing: Chemtura CORP - Form 10-Q

Condensed Consolidating Statement of Operations

Quarter ended June 30, 2014

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net sales	\$609	\$(531)	\$376	\$110	\$654
Cost of goods sold	451	(531)	307	92	583
Selling, general and administrative	67	—	36	4	27
Depreciation and amortization	25	—	7	7	11
Research and development	10	—	4	1	5
Facility closures, severance and related costs	4	—	—	1	3
Operating income	52	—	22	5	25
Interest expense	(11)	—	(14)	—	3
Other (expense) income, net	(3)	—	(11)	—	8
Equity in net earnings of subsidiaries	—	(43)	43	—	—
Earnings from continuing operations before income taxes	38	(43)	40	5	36
Income tax benefit (expense)	5	—	(1)	—	6
Earnings from continuing operations	43	(43)	39	5	42
Loss on sale of discontinued operations, net of tax	(4)	—	—	(3)	(1)
Net earnings	\$39	\$(43)	\$39	\$2	\$41

Condensed Consolidating Statement of Operations

Six months ended June 30, 2014

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net sales	\$1,165	\$(1,023)	\$710	\$224	\$1,254
Cost of goods sold	887	(1,023)	590	191	1,129
Selling, general and administrative	127	—	70	8	49
Depreciation and amortization	53	—	13	15	25
Research and development	18	—	7	3	8
Facility closures, severance and related costs	6	—	2	1	3
Operating income	74	—	28	6	40
Interest expense	(23)	—	(27)	—	4
Other (expense) income, net	—	—	(11)	—	11
Equity in net earnings of subsidiaries	—	(56)	56	—	—
Earnings from continuing operations before income taxes	51	(56)	46	6	55
Income tax benefit (expense)	2	—	(1)	—	3
Earnings from continuing operations	53	(56)	45	6	58
Earnings from discontinued operations, net of tax	1	—	1	—	—
Loss on sale of discontinued operations, net of tax	(9)	—	(1)	(6)	(2)
Net earnings	\$45	\$(56)	\$45	\$—	\$56

Condensed Consolidating Statement of Comprehensive Income

Quarter ended June 30, 2014

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net earnings	\$39	\$(43)	\$39	\$2	\$41
Other comprehensive income, net of tax					
Foreign currency translation adjustments	12	—	2	—	10
Unrecognized pension and other post-retirement benefit costs	3	—	2	—	1
Comprehensive income	\$54	\$(43)	\$43	\$2	\$52

Condensed Consolidating Statement of Comprehensive Income

Six months ended June 30, 2014

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Net earnings	\$45	\$(56)	\$45	\$—	\$56
Other comprehensive income (loss), net of tax					
Foreign currency translation adjustments	6	—	3	—	3
Unrecognized pension and other post-retirement benefit costs	4	—	7	—	(3)
Comprehensive income	\$55	\$(56)	\$55	\$—	\$56

Condensed Consolidating Balance Sheet

As of December 31, 2014

(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
ASSETS					
Current assets	\$1,216	\$—	\$539	\$113	\$564
Intercompany receivables	—	(6,937)	3,094	2,752	1,091
Investment in subsidiaries	—	(4,923)	822	1,134	2,967
Property, plant and equipment	704	—	116	222	366
Goodwill	172	—	93	3	76
Other assets	575	—	448	36	91
Total assets	\$2,667	\$(11,860)	\$5,112	\$4,260	\$5,155
LIABILITIES AND EQUITY					
Current liabilities	\$405	\$—	\$155	\$44	\$206
Intercompany payables	—	(6,937)	2,971	3,031	935
Long-term debt	556	—	541	—	15
Other long-term liabilities	652	—	391	83	178
Total liabilities	1,613	(6,937)	4,058	3,158	1,334
Total equity	1,054	(4,923)	1,054	1,102	3,821
Total liabilities and equity	\$2,667	\$(11,860)	\$5,112	\$4,260	\$5,155

Condensed Consolidating Statement of Cash Flows
Six months ended June 30, 2014
(In millions)

	Consolidated	Eliminations	Parent Company	Guarantor Subsidiaries	Non- Guarantor Subsidiaries
Increase (decrease) to cash					
CASH FLOWS FROM OPERATING ACTIVITIES					
Net earnings	\$45	\$(56)) \$45	\$—	\$56
Adjustments to reconcile net earnings to net cash (used in) provided by operations:					
Loss on sale of discontinued operations	9	—	1	6	2
Depreciation and amortization	53	—	13	15	25
Share-based compensation expense	7	—	7	—	—
Changes in assets and liabilities, net	(146)) 56	(63)) (16)) (123)
Net cash (used in) provided by operations	(32)) —	3	5	(40)
CASH FLOWS FROM INVESTING ACTIVITIES					
Net proceeds from divestments	16	—	(2)) 9	9
Capital expenditures	(48)) —	(7)) (14)) (27)
Net cash used in investing activities	(32)) —	(9)) (5)) (18)
CASH FLOWS FROM FINANCING ACTIVITIES					
Proceeds from long term debt	14	—	—	—	14
Payments on long term debt	(112)) —	(111)) —	(1)
Payments on other short-term borrowings, net	(1)) —	—	—	(1)
Common shares acquired	(157)) —	(157)) —	—
Proceeds from exercise of stock options	6	—	6	—	—
Net cash (used in) provided by financing activities	(250)) —	(262)) —	12
CASH AND CASH EQUIVALENTS					
Effect of exchange rates on cash and cash equivalents	—	—	—	—	—
Change in cash and cash equivalents	(314)) —	(268)) —	(46)
Cash and cash equivalents at beginning of period	549	—	317	—	232
Cash and cash equivalents at end of period	\$235	\$—	\$49	\$—	\$186

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements included in Item 1 of this Form 10-Q.

FORWARD-LOOKING STATEMENTS

In addition to historical information, this Report contains "forward-looking statements" within the meaning of Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Exchange Act of 1934, as amended. We use words such as "anticipate," "believe," "intend," "estimate," "expect," "continue," "should," "could," "may," "plan," "p" "will" and similar expressions to identify forward-looking statements. Such statements include, among others, those concerning our expected financial performance and strategic and operational plans, as well as all assumptions, expectations, predictions, intentions or beliefs about future events. You are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause actual results to differ materially from those anticipated in the forward-looking statements.

Such risks and uncertainties include, but are not limited to:

• The cyclical nature of the global chemicals industry;

• Increases in the price of raw materials or energy and our ability to recover cost increases through increased selling prices for our products;

• Disruptions in the availability of raw materials or energy;

• Our ability to implement our growth strategies in rapidly growing markets and faster growing regions;

• Our ability to execute timely upon our portfolio management strategies and mid and long range business plans;

• Our ability to execute timely on our restructuring plan and achieve the expected cost reductions;

• Declines in general economic conditions;

• The ability to comply with product registration requirements of regulatory authorities, including the U.S. Food and Drug Administration (the "FDA") and European Union Registration, Evaluation and Authorization of Chemicals ("REACH") legislation;

• Current and future litigation, governmental investigations, prosecutions and administrative claims;

• Environmental, health and safety regulatory matters;

• Federal regulations aimed at increasing security at certain chemical production plants;

• Significant international operations and interests;

• Our ability to maintain adequate internal controls over financial reporting;

• Exchange rate and other currency risks;

• Our dependence upon a trained, dedicated sales force;

• Operating risks at our production facilities;

• Our ability to protect our patents or other intellectual property rights;

• Whether our patents may provide full protection against competing manufacturers;

• Our ability to remain technologically innovative and to offer improved products and services in a cost-effective manner;

• Our ability to reduce the risks of cyber incidents and protect our information technology;

• Our unfunded and underfunded defined benefit pension plans and post-retirement welfare benefit plans;

• Risks associated with strategic acquisitions and divestitures;

• Risks associated with possible climate change legislation, regulation and international accords;

• The ability to support the carrying value of the goodwill and long-lived assets related to our businesses;

• Whether we repurchase any additional shares of our common stock that our Board of Directors have authorized us to purchase and the terms on which any such repurchases are made; and

• Other risks and uncertainties described in our filings with the Securities and Exchange Commission including Item 1A, Risk Factors, in our Annual Report on Form 10-K.

These statements are based on our estimates and assumptions and on currently available information. The forward-looking statements include information concerning our possible or assumed future results of operations, and

our actual results may differ significantly from the results discussed. Forward-looking information is intended to reflect opinions as of the date this Form 10-Q was filed. We undertake no duty to update any forward-looking statements to conform the statements to actual results or changes in our operations.

OUR BUSINESS

We are a global, publicly traded specialty chemical company dedicated to delivering innovative, performance-driven engineered specialty chemical solutions which are used as additives, ingredients or intermediates that add value to our customers' end products. We are committed to global sustainability through “greener technology” and developing engineered chemical solutions that meet our customers’ evolving needs. We operate in a wide variety of end-use industries, including automotive, building and construction, electronics, lubricants, packaging and transportation. We are a leader in many of our key product lines and transact business in more than 80 countries. Our principal executive offices are located in Philadelphia, Pennsylvania and Middlebury, Connecticut.

The primary economic factors that influence the operations and net sales of our Industrial Performance Products (“Industrial Performance”) and Industrial Engineered Products (“Industrial Engineered”) segments (collectively referred to as “Industrials”) are demand conditions in industrial, electronics, energy, residential and commercial construction, and transportation markets. Other factors affecting our financial performance include industry capacity, customer demand, raw material and energy costs, and selling prices. Selling prices are heavily influenced by the global demand and supply for the products we produce and competitor behavior. We pursue selling prices that reflect the value our products deliver to our customers, while seeking to pass on higher costs for raw material and energy to preserve our profit margins.

Our Agrochemical Manufacturing segment represents ongoing supply agreements with Platform Specialty Products Corporation (“Platform”) which were entered into in November 2014 contemporaneously with the sale of our former Chemtura AgroSolutions business to Platform. The supply agreements with Platform are designed to recover the cash costs incurred to manufacture the products under the agreements.

SECOND QUARTER RESULTS

Given the sale of our Chemtura AgroSolutions business to Platform in November 2014, our discussion of the results of operations for the consolidated Company for 2015 compared with 2014 is less meaningful to investors due to the change in the nature of the operations associated with our Agrochemical Manufacturing business from a market participant to a supplier of products to Platform under the supply agreements.

We believe the most effective way to present to investors the change in results of continuing operations for 2015 compared with 2014 is to provide separate discussions of the changes in our consolidated results for Chemtura excluding the Agrochemical Manufacturing segment and then for the Agrochemical Manufacturing segment.

The following chart presents the results of operations of the consolidated Company including the Agrochemical Manufacturing segment through operating income. The chart then segregates the results of operations for the Agrochemical Manufacturing segment from the total for our Industrial Performance, Industrial Engineered and Corporate segments combined (collectively referred to as the “Core Segments”). The discussion of the components of operating income included in the section titled Overview - Core Segments reflects only those changes related to the Core Segments. A separate discussion regarding the changes in results of operations of the Agrochemical Manufacturing segment is presented in this section under the heading “Agrochemical Manufacturing”.

Components of net income which are not included in operating income are not directly affected by the sale of our Chemtura AgroSolutions business and, therefore, the discussion related to changes in those components for 2015 compared with 2014 represent changes to the Company as a whole.

Edgar Filing: Chemtura CORP - Form 10-Q

(in millions)	Quarter Ended June 30, 2015			Quarter Ended June 30, 2014		
	Consolidated	Agrochemical Core Manufacturing Segments		Consolidated	Agrochemical Core Manufacturing Segments	
Net Sales	\$464	\$ 37	\$427	\$609	\$ 140	\$469
Cost of goods sold (a)	350	26	324	451	80	371
Gross Profit (a)	114	11	103	158	60	98
Selling, general and administrative	41	—	41	67	19	48
Depreciation and amortization	24	1	23	25	2	23
Research and development	6	—	6	10	3	7
Facility closures, severance and related costs	—	—	—	4	—	4
Equity income	(1)—	(1)	—	—
Operating Income	\$44	\$ 10	\$34	\$52	\$36	\$16

(a) Excludes depreciation and amortization expense which are shown separately.

Overview - Core Segments

Consolidated net sales in our Core Segments for the second quarter of 2015 were \$427 million or \$42 million lower than the second quarter of 2014 due to lower sales volume and unfavorable product mix of \$26 million, unfavorable foreign currency translation of \$10 million and lower selling prices of \$6 million. We experienced lower overall volume in both our Industrial Engineered and Industrial Performance segments. Sales volume declines in our Industrial Engineered segment related primarily to the reduction in sales of flame retardants for flexible urethane foams used in furniture applications and the interruption in supply of elemental bromine due to a strike at a third-party supplier, partially offset by increased demand for our clear brine fluids, tin specialty products and flame retardants used in electronic applications. Sales volume in our Industrial Performance segment was affected by lower customer demand across most petroleum additive products and order timing. Overall selling prices were down primarily in our Industrial Performance segment due to contractual and negotiated agreements that require reductions in selling prices in the event of reductions in certain raw material costs, offset in part by increases in selling prices for flame retardant used in electronic applications by our Industrial Engineered segment. In addition, we continued to experience the effects of unfavorable foreign currency translation due to the strengthening of the U.S. Dollar against the major foreign currencies.

Gross profit for our Core Segments in the second quarter of 2015 was \$103 million, an increase of \$5 million compared with the second quarter of 2014. Gross profit as a percentage of net sales for our core segments increased to 24% for the second quarter of 2015 compared with 21% for the second quarter of 2014. The increase in gross profit was primarily due to lower raw material costs and net favorable foreign currency translation, partly offset by slightly lower sales volume, unfavorable product mix and lower selling prices.

Selling, general and administrative (“SG&A”) expenses of \$41 million were \$7 million lower than the second quarter of 2014. Our second quarter 2014 SG&A expenses included \$7 million of expenses we incurred in connection with the sale of our Chemtura AgroSolutions business. SG&A expenses in the second quarter of 2015 benefited from our various cost savings initiatives that we announced in 2014. These benefits were partly offset, however, by higher costs associated with our management incentive plans in 2015 compared with the prior year.

Other Non-Operating Income and Expense

The following discussion regarding income and expense outside of operating income is presented on a consolidated Company basis, which is the sum of the Core Segments and the Agrochemical Manufacturing segment.

Interest expense was \$8 million during the second quarter of 2015, \$3 million lower than 2014, which was primarily the result of our repayments of debt utilizing net after-tax cash proceeds from the sale of Chemtura AgroSolutions. Other expense, net was \$2 million in the second quarter of 2015 which was \$1 million lower than 2014. Other expense, net in the second quarter of 2015 included a gain of \$3 million related to the sale of the Platform shares. The remaining activity primarily reflected realized and unrealized foreign exchange gains or losses, most significantly related to the decline in the value of the U.S. Dollar to the Euro in the second quarter of 2015.

Income tax expense reported for the second quarter of 2015 was \$16 million compared with a benefit of \$5 million in the second quarter of 2014. The tax expense reported for the second quarter of 2015 reflected higher earnings and provided a full tax provision on our U.S. income, following the release of the U.S. valuation allowance in the fourth quarter of 2014. In 2014,

we concluded that the positive evidence outweighed the negative evidence that we can utilize our U.S. deferred tax assets before they expire. As a result we released a majority of our U.S. valuation allowance. The tax benefit reported in the second quarter of 2014 included a decrease in foreign income taxes of approximately \$15 million related to an unrecognized tax benefit that had been recorded for an international jurisdiction in prior years. The tax benefit was recorded after reaching an agreement with the international jurisdiction that effectively settled the prior year liability. In the second quarter of 2014, due to the continuing application of a valuation allowance against our U.S. deferred tax assets, we did not record an income statement tax provision on our U.S. income/(losses) reflecting the related expense/(benefit) as a reduction/(increase) in the valuation allowance.

Net earnings from continuing operations for the second quarter of 2015 were \$18 million, or \$0.26 per diluted share, as compared with \$43 million, or \$0.46 per diluted share, for the second quarter of 2014. Our 2014 results include the Chemtura AgroSolutions business prior to the sale of that business in November 2014.

The gain on sale of discontinued operations, net of tax for the second quarter of 2015, was \$1 million, or \$0.01 per diluted share, and related to the sale of our Consumer Products business. The loss on sale of discontinued operations, net of tax for the second quarter of 2014, was \$4 million, or \$0.04 per diluted share, which primarily represented the post-closing adjustments and obligations, settlement of working capital claims and fees associated with those adjustments and claims related to the sale our Consumer Products business.

The following tables describe the major factors impacting net sales and operating income for each of our segments:

Net Sales (in millions)	Industrial Performance Products	Industrial Engineered Products	Subtotal Core Segments	Agrochemical Manufacturing	Total	
Quarter Ended June 30, 2014	\$259	\$210	\$469	\$140	\$609	
Changes in selling prices	(8)2	(6)—	(6)
Unit volume and mix	(16)(10)(26)—	(26)
Foreign currency	(5)(5)(10)—	(10)
Divestiture	—	—	—	(103)(103)
Quarter Ended June 30, 2015	\$230	\$197	\$427	\$37	\$464	

Operating Income (in millions)	Industrial Performance Products	Industrial Engineered Products	General corporate expense	Facility closures, severance and related costs	Subtotal Core Segments	Agrochemical Manufacturing	Total	
Quarter Ended June 30, 2014	\$ 26	\$ 16	\$ (22) \$ (4) \$ 16	\$ 36	\$ 52	
Costs associated with the sale of Chemtura AgroSolutions	—	—	7	—	7	—	7	
Divestitures	—	—	—	—	—	(27)(27)
Subtotal	26	16	(15)(4)23	9	32	
Price over raw materials (a)	8	8	—	—	16	—	16	
Unit volume and mix	(7) (3)—	—	(10)—	(10)
Foreign currency	2	—	—	—	2	—	2	
Manufacturing cost and absorption	6	(6)—	—	—	—	—	
Distribution cost	(2) 2	—	—	—	—	—	
Depreciation and amortization expense	1	(1)—	—	—	1	1	
Facility closures, severance and related costs	—	—	—	4	4	—	4	
SGA&R	3	—	(2)—	1	—	1	
Other	1	(1)(2)—	(2)—	(2)
Quarter Ended June 30, 2015	\$ 38	\$ 15	\$ (19) \$ —	\$ 34	\$ 10	\$ 44	

Price over raw materials is the sum of the net changes in selling prices and the net changes in raw material costs between the two periods. As the reduction in the costs of certain raw materials result in certain circumstances in (a) reductions in selling prices under certain contractual and negotiated agreements, the change in selling prices net of changes in raw material costs provides a better measure of the impact of selling price changes on our profitability (referred to as "price over raw materials").

The following is a discussion of the results of our segments for the second quarter ended June 30, 2015.

Industrial Performance Products

Our Industrial Performance segment reported lower net sales and higher operating income for the second quarter of 2015 compared with the same quarter of 2014.

The decline in net sales was primarily the result of lower selling prices and reduced customer demand and customer order timing for our refrigeration lubricants, inhibitor, intermediates and detergent products coupled with unfavorable product mix in our urethane business. The lower selling prices were primarily related to our obligation to pass along certain reductions in raw material costs to our customers. The impact of the strengthening of the U.S. Dollar against major foreign currencies in 2015 compared to 2014 resulted in the value of net sales denominated in foreign currencies translating to lower U.S. Dollar sales this quarter compared to the second quarter of 2014.

Operating income improved this quarter compared with the second quarter of 2014 due to lower raw materials costs, lower manufacturing costs, and reduced SG&A and research and development ("R&D") (collectively "SGA&R") expense, which was primarily the result of implementing many of the cost reduction initiatives we announced in 2014. These benefits were partly offset by the lower volumes and unfavorable product mix noted above.

Industrial Engineered Products

Our Industrial Engineered segment reported lower net sales and slightly lower operating income for the second quarter of 2015 compared with the same quarter of 2014.

Volume declines versus a year ago are attributable primarily to the reduction in demand for flame retardants for flexible urethane foams used in furniture applications, reduction in customer demand for certain flame retardants used in rigid foam applications and the interruption in supply of elemental bromine due to a strike at a third-party supplier, partially offset by increased demand for our clear brine fluids, tin specialty products and flame retardants used in electronic applications. In addition, we discontinued the sales of certain phosphorus-based flame retardants in the second half of 2014 and their absence in the second quarter 2015 operating results affected year-over-year volume comparisons. Volume declines were partially offset by improved sales of flame retardants going into electronics applications, which also saw a significant increase in selling prices in the second quarter of 2015. In addition, clear brine fluids used in deep offshore oil and gas well exploration and tin specialty products saw volume increases compared to the prior year. The impact of the strengthening of the U.S. Dollar in 2015 compared to 2014 against major foreign currencies resulted in the value of net sales in foreign currency translating to lower U.S. Dollar sales compared to the second quarter of 2014.

Despite lower net sales, our Industrial Engineered segment reported only a slight decrease in operating income. The effect of volume declines and manufacturing cost increases on operating income were offset by the benefit of increased prices, lower raw material costs and lower distribution costs. Manufacturing cost increases were primarily related to the lower volume coupled with production interruptions at our plant that produces Emerald Innovation 3000TM.

Corporate

Included in corporate are costs of a general nature or managed on a corporate basis. These costs, net of allocations to the business segments, primarily represent corporate stewardship and administration activities together with costs associated with legacy activities and intangible asset amortization. Functional costs are allocated between the business segments and general corporate expense.

Corporate expense was \$19 million in the second quarter of 2015, which included amortization and depreciation expense of \$4 million. In comparison, corporate expense was \$22 million in the second quarter of 2014, which included amortization and depreciation expense of \$4 million. The decrease is primarily the result of \$7 million in non-recurring costs in 2014 related to the sale of our Chemtura AgroSolutions business offset by a net increase in our environmental reserves and higher costs under our management incentive plans in 2015 compared to last year.

Agrochemical Manufacturing

The results of the Agrochemical Manufacturing segment in 2015 is not comparable to the results in 2014 due to the change in the nature of the business subsequent to the sale of the Chemtura AgroSolutions business in November 2014. The supply agreements with Platform are designed to recover the cash costs incurred to manufacture the products under the agreements, excluding depreciation and amortization. The operating income of the Agrochemical Manufacturing segment primarily represents the amortization, net of accretion of the below-market contract obligation

established when the Chemtura

28

AgroSolutions business was sold in November 2014.

YEAR TO DATE RESULTS

The following chart presents the results of operations of the consolidated Company including the Agrochemical Manufacturing segment through operating income. The chart then segregates the results of operations for the Agrochemical Manufacturing segment from the total for our Core Segments.

(in millions)	Six months ended June 30, 2015			Six months ended June 30, 2014		
	Agrochemical Core			Agrochemical Core		
	Consolidated	Manufacturing	Segments	Consolidated	Manufacturing	Segments
Net Sales	\$902	\$68	\$834	\$1,165	\$241	\$924
Cost of goods sold (a)	690	47	643	887	139	748
Gross Profit (a)	212	21	191	278	102	176
Selling, general and administrative	77	1	76	127	34	93
Depreciation and amortization	48	2	46	53	5	48
Research and development	11	—	11	18	5	13
Facility closures, severance and related costs	1	—	1	6	—	6
Loss on sale of business (b)	3	—	3	—	—	—
Equity income	(1))—	(1))—	—	—
Operating Income	\$73	\$18	\$55	\$74	\$58	\$16

(a) Excludes depreciation and amortization expense which are shown separately.

(b) Loss on sale of business was reported in our Corporate segment and represents customary working capital and other adjustments and the sale of our wholly-owned subsidiary in Russia to Platform.

Overview - Core Segments

Consolidated net sales of our Core Segments for the six months ended June 30, 2015 were \$834 million or \$90 million lower than the six months ended June 30, 2014 due to lower sales volume of \$69 million, unfavorable foreign currency translation of \$20 million and lower selling prices of \$1 million. The majority of the volume decline related to our Industrial Engineered segment, although our Industrial Performance segment saw lower volume and overall unfavorable product mix. Additionally, we continue to experience the unfavorable effect of foreign currency translation on net sales as the strengthening of the U.S. Dollar against foreign currencies in 2015 compared to 2014 resulted in a lower value of U.S. Dollar sales in the first half of 2015 as compared with the same period in 2014. Sales volume declines in our Industrial Engineered segment related primarily to the reduction in sales of flame retardant for flexible urethane foams used in furniture applications coupled with the interruption in supply of elemental bromine due to a strike at a third-party supplier, offset in part by increased demand for Emerald Innovation 3000™, products used in electronic applications and clear brine fluids in the first half of 2015. In the first half of 2015, Industrial Performance experienced unfavorable product mix, particularly in urethane products, and lower volumes, particularly in intermediates and inhibitor products.

Gross profit for our Core Segments in the six months ended June 30, 2015 was \$191 million, an increase of \$15 million compared with the six months ended June 30, 2014. Gross profit as a percentage of net sales increased to 23% for the six months ended June 30, 2015 as compared with 19% for the six months ended June 30, 2014. The increase in gross profit was primarily due to lower raw material costs, favorable manufacturing costs and variances, favorable foreign currency translation and lower distribution costs, partly offset by lower sales volume and unfavorable product mix. Included in the six months ended June 30, 2014 was a \$6 million charge for excess inventory that did not reoccur in 2015.

SG&A expenses of \$76 million in the first half of 2015 were \$17 million lower than in the same half of 2014. Our SG&A for the first six months of 2014 included \$11 million of expenses we incurred in connection with the sale of our Chemtura AgroSolutions business. The first six months of 2015 benefited from our various cost savings initiatives that we announced at the end of 2014. These benefits, however, were offset in part by higher costs under our management incentive plans in 2015 compared to last year.

Other Non-Operating Income and Expense

The following discussion regarding income and expense outside of operating income is presented on a consolidated Company basis, which is the sum of the Core Segments and the Agrochemical Manufacturing segment.

29

Interest expense was \$16 million during the six months ended June 30, 2015, \$7 million lower than in the same six months of 2014, primarily the result of our repayments of debt utilizing net after-tax cash proceeds from the sale of Chemtura AgroSolutions.

Other income, net was \$9 million in the six months ended June 30, 2015 compared with less than \$1 million in the six months ended June 30, 2014. Other income, net in the six months ended June 30, 2015 included a gain of \$3 million related to the sale of the Platform shares. The remaining activity primarily reflected realized and unrealized foreign exchange gains or losses, most significantly related to the strengthening of the U.S. Dollar against foreign currencies in the first quarter of 2015.

Income tax expense reported for the six months ended June 30, 2015 was \$27 million compared with a benefit of \$2 million in the six months ended June 30, 2014. The tax expense reported in 2015 reflected higher earnings and recorded a full tax provision on our U.S. income, following the release of the U.S. valuation allowance in the fourth quarter of 2014. In 2014, we concluded that the positive evidence outweighed the negative evidence that we can utilize our U.S. deferred tax assets before they expire. As a result we released a majority of our U.S. valuation allowance. The tax expense reported in the six months ended June 30, 2014 included a decrease in foreign income taxes of approximately \$15 million related to an unrecognized tax benefit that had been recorded for an international jurisdiction in prior years. The tax benefit was recorded after reaching an agreement with the international jurisdiction that effectively settled the prior year liability. In the six months ended June 30, 2014, due to the continuing application of a valuation allowance against our U.S. deferred tax assets, we did not record an income statement tax provision on our U.S. income/(losses) reflecting the related expense/(benefit) as a reduction/(increase) in the valuation allowance. Net earnings from continuing operations for the six months ended June 30, 2015 were \$39 million, or \$0.56 per diluted share, as compared with \$53 million, or \$0.55 per diluted share, for the six months ended June 30, 2014. Our 2014 results included the Chemtura AgroSolutions business prior to the sale of that business in November 2014. Earnings from discontinued operations, net of tax for the six months ended